Disposition of 13296 shares by David Patience of Accelerate Diagnostics at 0.87 subject to Rule 16b-3
AXDX Stock | USD 1.70 0.13 8.28% |
Slightly above 56% of all Accelerate Diagnostics' investors are looking to take a long position. The analysis of overall sentiment of trading Accelerate Diagnostics stock suggests that some investors are interested at this time. Accelerate Diagnostics' investing sentiment can be driven by a variety of factors including economic data, Accelerate Diagnostics' earnings reports, geopolitical events, and overall market trends.
Accelerate |
Filed transaction by Accelerate Diagnostics Officer: Chief Financial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at gurufocus.com
Accelerate Diagnostics Fundamental Analysis
We analyze Accelerate Diagnostics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Accelerate Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Accelerate Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Accelerate Diagnostics is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Accelerate Diagnostics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Accelerate Diagnostics stock to make a market-neutral strategy. Peer analysis of Accelerate Diagnostics could also be used in its relative valuation, which is a method of valuing Accelerate Diagnostics by comparing valuation metrics with similar companies.
Peers
Accelerate Diagnostics Related Equities
AXGN | Axogen | 2.70 | ||||
IRMD | Iradimed | 2.01 | ||||
SRDX | SurModics | 1.06 | ||||
AORT | Artivion | 0.10 | ||||
ITGR | Integer Holdings | 0.47 | ||||
LIVN | LivaNova PLC | 0.83 | ||||
ELMD | Electromed | 1.03 | ||||
ANIK | Anika Therapeutics | 1.14 | ||||
LUNG | Pulmonx Corp | 1.21 | ||||
CNMD | CONMED | 1.51 | ||||
CVRX | CVRx | 1.66 | ||||
SGHT | Sight Sciences | 2.59 | ||||
AVNS | Avanos Medical | 2.91 | ||||
OFIX | Orthofix Medical | 3.15 | ||||
NPCE | Neuropace | 6.20 | ||||
KIDS | Orthopediatrics Corp | 6.84 |
Additional Tools for Accelerate Stock Analysis
When running Accelerate Diagnostics' price analysis, check to measure Accelerate Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Accelerate Diagnostics is operating at the current time. Most of Accelerate Diagnostics' value examination focuses on studying past and present price action to predict the probability of Accelerate Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Accelerate Diagnostics' price. Additionally, you may evaluate how the addition of Accelerate Diagnostics to your portfolios can decrease your overall portfolio volatility.